share_log

Sanofi | 6-K: Dupixent® Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

赛诺菲安万特 | 6-K:Dupixent®在第二项阳性3期试验中显着减少COPD恶化,加速FDA提交并确认成为第一个批准用于治疗这种严重疾病的生物制剂的潜力

SEC announcement ·  2023/12/01 12:19
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息